InsiderTrades.com logo
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel

NRXP Insider Trading

Insider Ownership Percentage: 25.70%
Insider Buying (Last 12 Months): $6,241,204.25
Insider Selling (Last 12 Months): $1,544,866.92

NRx Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at NRx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NRx Pharmaceuticals Share Price & Price History

Current Price: $0.69
Price Change: ▼ Price Decrease of -0.0101 (-1.44%)
As of 03/21/2023 04:51 PM ET

This chart shows the closing price history over time for NRXP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel

NRx Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2022Stephen H WillardCEOBuy50,000$1.17$58,500.0050,000View SEC Filing Icon  
12/16/2022Voorhees Seth VanCFOBuy30,000$1.10$33,000.0046,337View SEC Filing Icon  
12/7/2022Jonathan C JavittDirectorSell400,000$1.00$400,000.0012,899,997View SEC Filing Icon  
11/29/2022Daniel C JavittMajor ShareholderSell13,730$1.50$20,595.009,643,234View SEC Filing Icon  
11/28/2022Patrick John FlynnDirectorBuy1,750$1.25$2,187.501,750View SEC Filing Icon  
11/25/2022Voorhees Seth VanCFOBuy16,337$1.11$18,134.0716,377View SEC Filing Icon  
11/18/2022Chaim HurvitzDirectorBuy40,408$1.10$44,448.80500,000View SEC Filing Icon  
11/17/2022Daniel C JavittMajor ShareholderSell33,018$1.05$34,668.909,656,964View SEC Filing Icon  
11/16/2022Chaim HurvitzDirectorBuy287,812$0.99$284,933.88287,812View SEC Filing Icon  
11/11/2022Daniel C JavittMajor ShareholderSell49,200$1.01$49,692.009,823,701View SEC Filing Icon  
7/29/2022Daniel C JavittMajor ShareholderSell784,063$1.01$791,903.639,872,901View SEC Filing Icon  
6/6/2022Daniel C JavittMajor ShareholderSell115,657$0.67$77,490.1912,743,423View SEC Filing Icon  
6/3/2022Daniel C JavittMajor ShareholderSell243,596$0.70$170,517.2012,859,080View SEC Filing Icon  
6/1/2022Jonathan C JavittInsiderBuy100,000$58.00$5,800,000.00146,332View SEC Filing Icon  
9/15/2021Robert BesthofInsiderSell40,000$11.76$470,400.00View SEC Filing Icon  
8/23/2021Alessandra DaigneaultGeneral CounselSell33,715$13.11$442,003.65View SEC Filing Icon  
See Full Table
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel

SEC Filings (Institutional Ownership Changes) for NRx Pharmaceuticals (NASDAQ:NRXP)

6.09% of NRx Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NRXP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

NRx Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/13/2023Charles Schwab Investment Management Inc.43,732$49K0.0%N/A0.065%Search for SEC Filing on Google Icon
2/13/2023Geode Capital Management LLC378,667$0.42M0.0%+18.1%0.559%Search for SEC Filing on Google Icon
2/10/2023Bank of America Corp DE35,809$40K0.0%+10,884.4%0.053%Search for SEC Filing on Google Icon
2/10/2023HRT Financial LP26,501$29K0.0%N/A0.039%Search for SEC Filing on Google Icon
2/9/2023HBK Sorce Advisory LLC58,460$65K0.0%N/A0.086%Search for SEC Filing on Google Icon
1/31/2023AE Wealth Management LLC29,515$33K0.0%N/A0.044%Search for SEC Filing on Google Icon
1/27/2023Exchange Traded Concepts LLC26,924$30K0.0%+154.0%0.040%Search for SEC Filing on Google Icon
1/18/2023Exchange Traded Concepts LLC26,924$30K0.0%+154.0%0.040%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.1,440,265$1.07M0.0%+31.6%2.129%Search for SEC Filing on Google Icon
11/3/2022Texas Capital Bank Wealth Management Services Inc.63,290$47K0.0%N/A0.094%Search for SEC Filing on Google Icon
8/15/2022Millennium Management LLC296,815$0.18M0.0%N/A0.445%Search for SEC Filing on Google Icon
5/18/2022Ursa Fund Management LLC15,000$37K0.0%N/A0.023%Search for SEC Filing on Google Icon
5/16/2022State Street Corp114,240$0.28M0.0%+1,009.1%0.171%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC139,003$0.34M0.0%N/A0.209%Search for SEC Filing on Google Icon
5/13/2022Northern Trust Corp58,598$0.14M0.0%+61.5%0.088%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.1,075,317$2.63M0.0%-8.3%1.614%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.525,493$1.29M0.0%+1.9%0.789%Search for SEC Filing on Google Icon
5/12/2022Citigroup Inc.15,208$37K0.0%+355.1%0.023%Search for SEC Filing on Google Icon
5/11/2022Bank of New York Mellon Corp10,129$25K0.0%N/A0.015%Search for SEC Filing on Google Icon
4/29/2022United Asset Strategies Inc.18,300$45K0.0%N/A0.027%Search for SEC Filing on Google Icon
2/9/2022Wolverine Asset Management LLC37,105$0.18M0.0%-12.8%0.063%Search for SEC Filing on Google Icon
2/8/2022Raymond James Financial Services Advisors Inc.11,567$55K0.0%N/A0.020%Search for SEC Filing on Google Icon
11/15/2021Penserra Capital Management LLC2,956$27K0.0%N/A0.005%Search for SEC Filing on Google Icon
11/12/2021Wolverine Asset Management LLC42,568$0.39M0.0%+118.4%0.079%Search for SEC Filing on Google Icon
11/5/2021Advisor Group Holdings Inc.42,885$0.40M0.0%+1,197.6%0.080%Search for SEC Filing on Google Icon
11/2/2021Cambridge Investment Research Advisors Inc.153,523$1.42M0.0%N/A0.285%Search for SEC Filing on Google Icon
8/16/2021Owl Creek Asset Management L.P.300,000$3.40M0.2%N/A0.626%Search for SEC Filing on Google Icon
8/16/2021Ionic Capital Management LLC35,721$0.42M0.0%N/A0.075%Search for SEC Filing on Google Icon
8/16/2021Linden Advisors LP364,352$4.23M0.0%N/A0.760%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp130,633$1.52M0.0%N/A0.273%Search for SEC Filing on Google Icon
8/13/2021Yakira Capital Management Inc.11,923$0.14M0.0%N/A0.025%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC34,475$0.40M0.0%N/A0.072%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.637,416$7.41M0.0%N/A1.330%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
NRx Pharmaceuticals logo
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
Read More on NRx Pharmaceuticals

Today's Range

Now: $0.69
Low: $0.68
High: $0.72

50 Day Range

MA: $1.06
Low: $0.66
High: $1.40

52 Week Range

Now: $0.69
Low: $0.49
High: $3.03

Volume

103,476 shs

Average Volume

214,766 shs

Market Capitalization

$46.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Who are the company insiders with the largest holdings of NRx Pharmaceuticals?

NRx Pharmaceuticals' top insider investors include:
  1. Jonathan C Javitt (Director)
  2. Daniel C Javitt (Major Shareholder)
  3. Chaim Hurvitz (Director)
  4. Jonathan C Javitt (Insider)
  5. Stephen H Willard (CEO)
  6. Voorhees Seth Van (CFO)
  7. Patrick John Flynn (Director)
  8. Alessandra Daigneault (General Counsel)
  9. Robert Besthof (Insider)
Learn More about top insider investors at NRx Pharmaceuticals.

Who are the major institutional investors of NRx Pharmaceuticals?

NRx Pharmaceuticals' top institutional investors include:
  1. Geode Capital Management LLC — 0.56%
  2. HBK Sorce Advisory LLC — 0.09%
  3. Charles Schwab Investment Management Inc. — 0.06%
  4. Bank of America Corp DE — 0.05%
  5. AE Wealth Management LLC — 0.04%
  6. Susquehanna International Group LLP — 0.00%
Learn More about top institutional investors of NRx Pharmaceuticals stock.

Which institutional investors are selling NRx Pharmaceuticals stock?

In the previous quarter, NRXP stock was sold by these institutional investors:
  1. Susquehanna International Group LLP
  2. Simplex Trading LLC
  3. Group One Trading L.P.
Within the previous year, company insiders that have sold NRx Pharmaceuticals company stock include:
  1. Jonathan C Javitt (Director)
  2. Daniel C Javitt (Major Shareholder)
Learn More investors selling NRx Pharmaceuticals stock.

Which institutional investors are buying NRx Pharmaceuticals stock?

In the last quarter, NRXP stock was acquired by institutional investors including:
  1. HBK Sorce Advisory LLC
  2. Geode Capital Management LLC
  3. Charles Schwab Investment Management Inc.
  4. Bank of America Corp DE
  5. AE Wealth Management LLC
  6. HRT Financial LP
  7. Exchange Traded Concepts LLC
  8. Exchange Traded Concepts LLC
In the previous year, these company insiders have bought NRx Pharmaceuticals stock:
  1. Jonathan C Javitt (Director)
  2. Daniel C Javitt (Major Shareholder)
  3. Chaim Hurvitz (Director)
  4. Jonathan C Javitt (Insider)
  5. Stephen H Willard (CEO)
Learn More investors buying NRx Pharmaceuticals stock.
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel